632 results match your criteria Prostate Cancer - Cryotherapy


Cryosurgery Versus Primary Androgen Deprivation Therapy for Locally Recurrent Prostate Cancer After Primary Radiotherapy: A Propensity-Matched Survival Analysis.

Cureus 2020 May 6;12(5):e7983. Epub 2020 May 6.

Canadian Clincial Trials Group, Queen's University, Kingston, CAN.

Background Optimal management of isolated local recurrence of prostate cancer after primary radiotherapy remains to be defined. Up-front androgen deprivation therapy (ADT) is widely used but may adversely affect the quality of life and is essentially a palliative treatment. Local salvage carries a different side-effect profile and is potentially curative, but it has not been compared to ADT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7983DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7205382PMC

Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial.

Contemp Clin Trials 2020 Jun 14;93:105999. Epub 2020 Apr 14.

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK; Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Introduction: Focal therapy (FT) targets individual areas of cancer within the prostate, providing oncological control with minimal side-effects. Early evidence demonstrates encouraging short-medium-term outcomes. With no randomized controlled trials (RCT) comparing FT to radical therapies, Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (CHRONOS) will compare the cancer control of these two strategies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cct.2020.105999DOI Listing
June 2020
1.986 Impact Factor

Influence of sociodemographic factors on treatment's choice for localized prostate cancer in Portugal.

Arch Ital Urol Androl 2020 Apr 6;92(1):45-49. Epub 2020 Apr 6.

Urology Department, Instituto Português de Oncologia Francisco Gentil, Coimbra.

Introduction: Patients with localized prostate cancer (PCa) are active participants in the choice of treatment.

Objectives: To access the effects of social and demographic factors in the choice of treatment in cases of localized PCa, in a Portuguese population.

Methods: Identification of all patients with the diagnosis of localized PCa in the last four years in an oncological centre. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4081/aiua.2020.1.45DOI Listing

An Exploratory Study of Dose Escalation Standard Focal High-Intensity Focused Ultrasound for Treating Nonmetastatic Prostate Cancer.

J Endourol 2020 May 5. Epub 2020 May 5.

Imperial Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.

Analysis of treatment success regarding oncological recurrence rate between standard and dose escalation focal high-intensity focused ultrasound (HIFU) of prostate cancer. In this analysis of our prospectively maintained HIFU (Sonablate 500) database, 598 patients were identified who underwent a focal HIFU (Sonablate 500) between March 2007 and November 2016. Follow-up occurred with 3-monthly clinic visits and prostate specific antigen (PSA) testing in the first year. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/end.2019.0613DOI Listing

Management of erectile dysfunction and LUTS/incontinence: the two most common, long-term side effects of prostate cancer treatment.

Can J Urol 2020 Feb;27(1S1):17-24

Division of Urology, University Health Network, University of Toronto, Toronto, Ontario, Canada.

The two major long-term concerns associated with different options for the management of prostate cancer, (including surgery, radiotherapy, brachytherapy, cryotherapy, HIFU, etc.) include difficulties with lower urinary tract symptoms (LUTS) and/or erectile dysfunction. LUTS can be in the form of stress urinary incontinence (SUI), urge urinary incontinence (UUI), frequency/urgency, and/or voiding difficulties. Read More

View Article

Download full-text PDF

Source
February 2020

Cytoreductive cryotherapy for newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Prostate Cancer Prostatic Dis 2020 Feb 19. Epub 2020 Feb 19.

Imperial Prostate, Division of Surgery, Department of Surgery and Cancer, Imperial College London, Charing Cross Hospital, London, W6 8RF, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-020-0216-4DOI Listing
February 2020

Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Prostate Cancer Prostatic Dis 2020 Jun 12;23(2):232-243. Epub 2020 Feb 12.

Royal Surrey NHS Foundation Trust, Guildford, Surrey, GU2 7XX, UK.

Background: Prostate cancer focal therapy aims to minimize the side-effects of whole gland treatments, such as radical prostatectomy and radiotherapy without compromising oncological efficacy. However, concerns exist regarding the multifocal nature of prostate cancer and the lack of long-term oncological data for this form of treatment. In recent years, the routine adoption of multi-parametric magnetic resonance imaging (mpMRI) of the prostate has improved our ability to select candidates for focal therapy and to accurately deliver this form of prostate cancer treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-020-0206-6DOI Listing
June 2020
3.425 Impact Factor

Whole and hemi-gland cryoablation for primary localized prostate cancer: Short and medium-term oncological and functional outcomes.

Actas Urol Esp 2020 Apr 5;44(3):172-178. Epub 2020 Feb 5.

Departamento de Urología, Fundació Puigvert, Universidad Autónoma de Barcelona, Barcelona, España.

Introduction: To compare oncological, functional and post-operative outcomes of hemi (HC) vs. whole gland (WGC) cryoablation as first line treatment of localized prostate cancer.

Material And Method: Sixty-six consecutive patients undertaking whole-gland cryoablation (WGC=40) or hemi-cryoablation (HC=26) in a tertiary referral centre between 2010 and 2018 were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.acuro.2019.10.003DOI Listing

Prostate Multiparametric Magnetic Resonance Imaging Features Following Partial Gland Cryoablation.

Urology 2020 Apr 15;138:98-105. Epub 2020 Jan 15.

Department of Urology, New York Presbyterian Hospital, Weill Cornell Medicine, New York, NY. Electronic address:

Objective: To assess the qualitative and quantitative changes on prostate multiparametric magnetic resonance imaging (mpMRI) following partial gland ablation (PGA) with cryotherapy and correlate with histopathology.

Methods: We used 3D Slicer to generate prostate models and segment ipsilateral (treated) and contralateral peripheral and transition zones in 10 men who underwent MRI/transrectal ultrasound fusion-guided PGA during 2017-2018. Pre- and post-PGA volumes of prostate segments were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2020.01.005DOI Listing

Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer.

Clin Genitourin Cancer 2019 Dec 5. Epub 2019 Dec 5.

Division of Urology, Department of Surgery, Duke University Medical Center, Durham, NC. Electronic address:

Background: We compared the short-term oncologic and functional outcomes of salvage focal cryotherapy (SFC) with those of salvage total cryotherapy (STC) for radiotherapy (RT)-persistent/recurrent prostate cancer.

Materials And Methods: We queried the Cryo On-Line Database registry for men who had undergone SFC and STC of the prostate for RT-persistent or recurrent disease. Propensity score weighting was used to match age at treatment, presalvage therapy prostate-specific antigen level, Gleason sum, and presalvage cryotherapy androgen deprivation therapy status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.11.009DOI Listing
December 2019

Salvage radical prostatectomy following focal therapy: functional and oncological outcomes.

BJU Int 2020 Apr 9;125(4):525-530. Epub 2020 Jan 9.

Division of Urology, Department of Surgical Oncology, University Health Network, University of Toronto, Toronto, ON, Canada.

Objectives: To report the oncological and functional outcomes of salvage radical prostatectomy (sRP) after focal therapy (FT).

Patients And Methods: A retrospective review of all patients who underwent sRP after FT was performed. Clinical and pathological outcomes focussed on surgical complications, oncological, and functional outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14976DOI Listing
April 2020
3.533 Impact Factor

Interventional therapy in malignant conditions of the prostate.

Radiologe 2019 Dec;59(Suppl 1):28-39

Klinik für Strahlentherapie, MediClin Robert Janker Klinik, Bonn, Germany.

Interventional therapies are emerging modalities for the treatment of localized prostate cancer. Their aim is to reduce the morbidity associated with radical therapies (rT) by minimizing damage to non-cancerous tissue, with priority given to sparing key structures such as the neurovascular bundles, external sphincter, bladder neck, and rectum, while maintaining local cancer control. Interventional ablative technologies deliver energy in different ways to destroy cancer cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00117-019-00632-xDOI Listing
December 2019
5 Reads

Phase I study of cancer lesion-targeted microwave coagulation therapy for localized prostate cancer: A pilot clinical study protocol.

Contemp Clin Trials Commun 2019 Dec 12;16:100471. Epub 2019 Oct 12.

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Background: Whole-gland therapy for prostate cancer, which might cause more harm than no therapy (observation or active surveillance), might be a overtreatment. In order to avoid overtreatment as well as undertreatment of localize prostate cancer, novel strategy of organ-preserving therapies have been developed to achieve both cancer control and functional preservation. For the therapeutic techniques, microwave ablation would be an option for lesion-targeted focal therapy to eradicate biopsy-proven cancer lesion with its safety margin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.conctc.2019.100471DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831715PMC
December 2019

A pilot trial of pembrolizumab plus prostatic cryotherapy for men with newly diagnosed oligometastatic hormone-sensitive prostate cancer.

Prostate Cancer Prostatic Dis 2020 03 14;23(1):184-193. Epub 2019 Oct 14.

Department of Urology, The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.

Background: Monotherapy with immune checkpoint inhibitors has generally been unsuccessful in men with advanced prostate cancer. Preclinical data support the notion that cryotherapy may improve immune-mediated and anti-tumor responses. The objective of this study was to assess the safety and feasibility of whole-prostate gland cryotherapy combined with pembrolizumab and androgen deprivation in men with oligometastatic hormone-sensitive prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41391-019-0176-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7031012PMC
March 2020
1 Read

The Scottish prostate cryotherapy service-the role of the clinical nurse specialist.

Br J Nurs 2019 Oct;28(18):S12-S16

Professor, CRUK Beatson Institute for Cancer Research, Glasgow/Institute of Cancer Sciences, University of Glasgow.

This article outlines the role of the clinical nurse specialist in establishing a Scotland-wide national designated service for prostate cryotherapy for patients with radiation-recurrent prostate cancer. The service was established in 2009 and provides prostate cryotherapy across Scotland. This article reviews and discusses the challenges involved in setting up a new service for tertiary treatment as well as highlighting the key achievements of the service. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/bjon.2019.28.18.S12DOI Listing
October 2019
1 Read

Assessment of Return to Baseline Urinary and Sexual Function Following Primary Focal Cryotherapy for Nonmetastatic Prostate Cancer.

Eur Urol Focus 2019 Oct 4. Epub 2019 Oct 4.

Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Background: The oncological outcomes in men with clinically significant prostate cancer following focal cryotherapy are promising, although functional outcomes are under-reported.

Objective: To determine the impact of focal cryotherapy on urinary and sexual function, specifically assessing return to baseline function.

Design, Setting, And Participants: Between October 2013 and November 2016, 58 of 122 men who underwent focal cryotherapy for predominantly anterior clinically significant localised prostate cancer within a prospective registry returned patient-reported outcome measure questionnaires, which included International Prostate Symptom Score (IPSS) and International Index of Erectile Function (IIEF-15) questionnaires. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euf.2019.09.004DOI Listing
October 2019
2 Reads

[Prostate cryotherapy: General principles.]

Arch Esp Urol 2019 Oct;72(8):816-824

Unidad de Andrología y Cirugía Reconstructiva Uretro-Genital. Servicio de Urología. Hospital General Universitario Gregorio Marañón. Madrid. España.

Introduction: Prostate cryotherapy has been consolidated as an alternative minimally invasive treatment.

Objective: To exposed its historical development, its action mechanism and the surgical technique. Regarding its indications, we expose the different option of treatment- primary cryotherapy, salvage and focal- emphasizing its oncological results in the absence of randomized studies. Read More

View Article

Download full-text PDF

Source
October 2019
1 Read

Active treatment in low-risk prostate cancer: a population-based study.

Curr Oncol 2019 08 1;26(4):e535-e540. Epub 2019 Aug 1.

Tom Baker Cancer Centre, Calgary, AB.

Background: Active surveillance instead of active treatment (at) is preferred for patients with low-risk prostate cancer (lr-pca), but practice varies widely. We conducted a population-based study to assess the proportion of patients who underwent at between January 2011 and December 2014, and to evaluate factors associated with at.

Methods: The provincial cancer registry was linked to administrative health datasets to identify patients with lr-pca and to acquire demographic, tumour, and treatment data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3747/co.26.4953DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6726256PMC
August 2019
2 Reads

Focal Therapy for Localized Prostate Cancer with Either High Intensity Focused Ultrasound or Cryoablation: A Single Institution Experience.

J Urol 2020 02 22;203(2):320-330. Epub 2019 Aug 22.

Department of Urology, Institut Mutualiste Montsouris, Université Paris-Descartes, Paris, France.

Purpose: We report oncologic outcomes in patients treated with focal therapy for prostate cancer.

Materials And Methods: We retrospectively analyzed a single institution cohort of men with localized prostate cancer who received focal therapy using high intensity focused ultrasound or cryotherapy from 2009 to 2018. Focal therapy was offered for low or intermediate risk disease (prostate specific antigen less than 20 ng/ml, Gleason score 7 or less and clinical stage T2b or less). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JU.0000000000000506DOI Listing
February 2020
1 Read

Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-analysis.

Eur Urol Oncol 2020 Apr 24;3(2):183-197. Epub 2019 Jan 24.

Department of Radiation Oncology, A.O.U. Careggi, University of Florence, Florence, Italy.

Context: Different nonsurgical therapeutic strategies can be adopted for intraprostatic relapse of prostate cancer after primary radiotherapy, including re-irradiation (with brachytherapy [BT] or external beam radiotherapy [EBRT]), high-intensity focused ultrasound (HIFU), and cryotherapy. The main issues to consider when choosing nonsurgical salvage local therapies are local tumor control and significant genitourinary toxicity.

Objective: To conduct a systematic review and meta-analysis of the role of nonsurgical salvage modalities in patients with radiorecurrent prostate cancer and associated clinical outcomes and toxicity profiles. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2018.12.011DOI Listing
April 2020
5 Reads

Consulting "Dr. Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis.

Eur Urol Oncol 2019 Jul 30. Epub 2019 Jul 30.

Department of Urology, University of Verona, Verona, Italy.

Background: In the era of digital data, the Internet has become the primary source from which individuals draw healthcare information.

Objective: The aim of the present study is to determine worldwide public interest in prostate cancer (PCa) treatments, their penetrance and variation, and how they compare over time.

Design, Setting, And Participants: An analysis of worldwide search-engine trends included electronic Google queries from people who searched PCa treatment options from January 2004 to August 2018, worldwide. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.euo.2019.07.002DOI Listing
July 2019
4 Reads

Rectal wall saline displacement for improved margin during MRI-guided cryoablation of primary and recurrent prostate cancer.

Abdom Radiol (NY) 2020 04;45(4):1155-1161

Department of Urology, Mayo Clinic, Rochester, MN, USA.

Purpose: To describe safety, efficacy, and added oncologic margin of saline displacement of the rectal wall during MRI-guided cryoablation of primary and recurrent prostate cancer.

Methods: A retrospective review was conducted for patients who underwent MRI-guided cryoablation with saline displacement of the rectal wall for treatment of primary and recurrent prostate cancer over a 2-year period. Saline displacement was used when the distance from the edge of the ablation area to the rectal wall was insufficient to provide at least a 5-mm treatment margin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00261-019-02147-4DOI Listing
April 2020
3 Reads

Salvage cryoablation for local recurrence of prostatic cancer after curative therapy.

Diagn Interv Imaging 2019 Nov 19;100(11):679-687. Epub 2019 Jul 19.

Department of Radiology, Hôpital Saint-Louis, APHP & Université de Paris-Diderot Paris 7, 75010 Paris, France.

Purpose: The purpose of this study was to determine the efficacy of salvage cryotherapy for intra-prostatic and local extraprostatic recurrences after curative treatment of prostate adenocarcinoma.

Material And Method: Twenty-eight men (mean age, 69±6 [SD] years; range: 51-82 years) treated with cryoablation for prostatic (N=21) or extraprostatic (N=7) recurrent prostate cancer after radiotherapy with or without associated prostatectomy were included. Technical success, complication and recurrences were reported. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.diii.2019.07.001DOI Listing
November 2019
6 Reads

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis.

Urol Oncol 2019 10 8;37(10):637-646. Epub 2019 Jul 8.

Department of Urology, Medical University of Vienna, Vienna, Austria; Karl Landsteiner Institute of Urology and Andrology, Vienna, Austria; Department of Urology, Weill Cornell Medical College, New York, NY; Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX; Institute for Urology and Reproductive Health, Sechenov University, Moscow, Russia. Electronic address:

Aim: To evaluate the association between testosterone replacement therapy (TRT) in prostate cancer (CaP) patients who underwent definitive local therapy with curative intent with biochemical recurrence (BCR).

Materials And Methods: A literature search using PubMed, Scopus, Web of Science, and Cochrane Library was conducted on November 2018 to identify relevant studies according to the Preferred Reporting Items for Systematic Review and Meta Analysis guidelines. The pooled BCR rate in CaP men treated with TRT after definitive local therapy with curative intent was calculated using a random effects model. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.06.007DOI Listing
October 2019
21 Reads
2.768 Impact Factor

Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.

Clin Genitourin Cancer 2019 08 28;17(4):e831-e836. Epub 2019 May 28.

Division of Urologic Surgery, Duke Cancer Institute, Duke University Hospital, Durham, NC- 2 Department of Urology, Shiraz University of Medical Sciences, Shiraz, Iran.

Background: The purpose of the study was to examine the outcomes of salvage prostate cryoablation for managing patients with local recurrence after primary cryotherapy.

Patients And Methods: The records of 108 patients treated with salvage prostate cryoablation for biopsy-proven local recurrence after primary cryotherapy were retrospectively reviewed. Oncological outcome was defined by the rate of biochemical recurrence (BCR) after salvage ablation using Phoenix criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clgc.2019.05.014DOI Listing
August 2019
6 Reads

'Dr Google': trends in online interest in prostate cancer screening, diagnosis and treatment.

BJU Int 2019 Jun 17. Epub 2019 Jun 17.

Section of Urology, Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon.

Objectives: To examine trends in online search behaviours related to prostate cancer on a national and regional scale using a dominant major search engine.

Materials And Methods: Google Trends was queried using the terms 'prostate cancer', 'prostate-specific antigen' (PSA), and 'prostate biopsy' between January 2004 and January 2019. Search volume index (SVI), a measure of relative search volume on Google, was obtained for all terms and examined by region and time period: pre-US Preventive Services Task Force (USPSTF) Grade D draft recommendation on PSA screening; during the active Grade D recommendation; and after publication of the recent Grade C draft recommendation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.14846DOI Listing
June 2019
19 Reads

Reply to Zhipeng Mai's Letter to the Editor re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105.

Eur Urol 2019 Sep 29;76(3):e63-e64. Epub 2019 May 29.

Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.05.023DOI Listing
September 2019
9 Reads

Re: Taimur T. Shah, Max Peters, David Eldred-Evans, et al. Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. Eur Urol 2019;76:98-105.

Authors:
Zhipeng Mai

Eur Urol 2019 Sep 29;76(3):e61-e62. Epub 2019 May 29.

Department of Urology, Zhongshan City People's Hospital, Zhongshan, People's Republic of China. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.05.024DOI Listing
September 2019
4 Reads

A review of salvage treatment options for disease progression after radiation therapy for localized prostate cancer.

Urol Oncol 2019 09 24;37(9):582-598. Epub 2019 May 24.

Department of Radiation Oncology, Indiana University School of Medicine, Indianapolis, IN; Indiana University Simon Cancer Center, Indianapolis, IN. Electronic address:

Recurrence of prostate cancer after initial treatment with radiation therapy (RT) is highly dependent on pretreatment risk group and unfortunately, a proportion of patients fail primary treatment. The treatment of recurrence after primary radiation is rapidly changing with advances in imaging and it is important to distinguish those with a local failure from those with distant failure. If disease remains locally confined, salvage treatment with a variety of techniques can still provide a potential cure. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urolonc.2019.04.030DOI Listing
September 2019
8 Reads

Salvage Cryoablation for Radiorecurrent Prostate Cancer: Initial Experience at a Regional Health Care System.

Perm J 2019 ;23

Department of Urology, Los Angeles Medical Center, CA.

Context: Local recurrence after radiotherapy for prostate cancer remains challenging to treat effectively. Although oncologic control is highest with salvage prostatectomy, the procedure is associated with substantial morbidity.

Objective: To identify factors associated with successful salvage cryoablation for radiorecurrent prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7812/TPP/18-153DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499118PMC
February 2020
6 Reads

Comprehensive Evaluation of Focal Therapy Complications in Prostate Cancer: A Standardized Methodology.

J Endourol 2019 07 31;33(7):509-515. Epub 2019 May 31.

1 Department of Urology, Institut Mutualiste Montsouris, Paris, France.

Today, up to one-third of newly diagnosed prostate cancer (PCa) cases may be suitable for focal treatment. The lack of data about the toxicity profiles of lesion-targeting therapies, however, has made it difficult to compare treatment modalities. The aim of the present study was to evaluate comprehensively the incidence, severity, and timing of onset of complications for PCa patients undergoing focal high-intensity focused ultrasound (HIFU) and focal cryosurgical ablation of the prostate (CSAP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/end.2018.0809DOI Listing
July 2019
15 Reads

Salvage treatment for radio-recurrent prostate cancer: a review of literature with focus on recent advancements in image-guided focal salvage therapies.

Int Urol Nephrol 2019 Jul 12;51(7):1101-1106. Epub 2019 Apr 12.

Division of Urology, University of Cincinnati Cancer Institute, University of Cincinnati College of Medicine, 231 Albert Sabin Way, ML 0589, Cincinnati, OH, 45267, USA.

Biochemical recurrence of prostate cancer occurs in 25-33% of patients who undergo radiation therapy (RT). Unfortunately, greater than 90% of patients with radiation recurrence undergo androgen deprivation therapy (ADT), despite the detrimental side effect profile and the lack of supporting evidence for ADT use in local recurrence. In patients who experience recurrence after treatment with RT, options for treatment include salvage radical prostatectomy (SRP), salvage cryotherapy (SCT), salvage brachytherapy (SBT), and high-intensity focused ultrasound (HIFU). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11255-019-02114-4DOI Listing
July 2019
12 Reads

F-Fluciclovine Parameters on Targeted Prostate Biopsy Associated with True Positivity in Recurrent Prostate Cancer.

J Nucl Med 2019 11 6;60(11):1531-1536. Epub 2019 Apr 6.

Department of Radiology and Imaging Sciences, Emory University School of Medicine, Atlanta, Georgia

We evaluated F-fluciclovine uptake parameters that correlate with true positivity for local recurrence in non-prostatectomy-treated patients. Twenty-one patients (prostate-specific antigen level, 7.4 ± 6. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.119.227033DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6836857PMC
November 2019
7 Reads

Salvage robot-assisted radical prostatectomy following failed local treatments.

Arch Esp Urol 2019 04;72(3):277-282

Lyx Institute of Urology. Madrid. Spain. University Hospital Puerta de Hierro-Majadahonda. Madrid. Spain.

Prostate cancer represents the most commonly diagnosed cancer in men and is the second-leading cause of cancer related death in the United States. Primary treatment for prostate cancer includes radiotherapy or ablative procedures such as cryotherapy, and high-intensity focused ultrasound (HIFU). Unfortunately, a large proportion of these patients, especially with high risk features, may experience disease recurrence within 10 years. Read More

View Article

Download full-text PDF

Source
April 2019
9 Reads

Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence.

Eur Urol 2019 Jul 21;76(1):27-30. Epub 2019 Mar 21.

Urology Centre, Guy's and St. Thomas NHS Foundation Trust, London, UK. Electronic address:

There are few data on the outcomes and toxicity of radical prostatectomy (RP) among men experiencing local recurrence of prostate cancer (PC) following focal therapy (FT). To characterise perioperative, oncological, and functional outcomes after salvage robot-assisted RP (S-RALP) and determine the risk factors for S-RALP failure, we conducted a multicentre cohort study of 82 patients undergoing S-RALP after FT. All had histological confirmation of PC recurrence, with metastatic disease excluded using pelvic magnetic resonance imaging, a bone scan, and/or positron emission tomography/computed tomography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.eururo.2019.03.007DOI Listing
July 2019
14 Reads

Contemporary treatments in prostate cancer focal therapy.

Curr Opin Oncol 2019 05;31(3):200-206

Urologic Oncology Branch (UOB), National Cancer Institute (NCI).

Purpose Of Review: Radical treatments for prostate cancer are associated with significant morbidity, including incontinence and erectile dysfunction. Advances in the field of prostate MRI and desire to reduce treatment morbidities have led to a rapid growth in focal treatments for prostate cancer. Here, we review novel focal prostate cancer treatments and their associated recent clinical data, with a particular focus on data reported within the last 24 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000515DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6465079PMC
May 2019
9 Reads

Future of focal therapy for the treatment of prostate cancer- european section of urotechnology (ESUT) position.

Arch Esp Urol 2019 Mar;72(2):167-173

Department of Urology. La Paz University Hospital. Madrid. Spain. Instituto de Investigación Hospital Universitario La Paz (IdiPAZ). Madrid. Spain.

Introduction: Focal therapy (FT) is a treatment option for prostate cancer (PCa), which offers the possibility of an effective therapy in selected patients who have the localized disease, with a significant reduction in treatment related morbidity. Based on the current status of FT, our objective was to determine the most appropriate strategy to improve patient management.

Materials And Methods: A literature review was done performed through the PubMed database and focused on the following topics: localised prostate cancer,MRI, prostate biopsies, ablative therapy and focal therapy. Read More

View Article

Download full-text PDF

Source
March 2019
8 Reads

Misinformation on the Internet regarding Ablative Therapies for Prostate Cancer.

Urology 2019 11 26;133:182-186. Epub 2019 Feb 26.

Department of Urology, Columbia University Medical Center, New York, NY.

Objective: To evaluate the quality of web-based information on ablative therapies for prostate cancer.

Methods: The 2 most common search engines (Google and Bing) were queried for the following terms: "prostate cancer" + "HIFU" and "cryotherapy," respectively. The top 50 websites for each were obtained. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.12.050DOI Listing
November 2019
10 Reads

The role of MRI for detection and staging of radio- and focal therapy-recurrent prostate cancer.

World J Urol 2019 Aug 20;37(8):1485-1490. Epub 2019 Feb 20.

Department of Urology, Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.

Local recurrent prostate cancer after radical treatment is found in the majority of men with a rising PSA. Salvage treatment procedures for recurrent disease, such as radiation therapy and ablative procedures, can provide long-term responses in well-selected cases. Prostate magnetic resonance imaging (MRI) allows diagnosis and staging, and the value provides information on treatment selection, treatment planning and treatment guidance in local recurrent prostate cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00345-019-02677-yDOI Listing
August 2019
5 Reads

Unusual endobronchial prostatic metastatic tumor occluding right main bronchus.

Asian Cardiovasc Thorac Ann 2019 Mar 23;27(3):228-230. Epub 2019 Jan 23.

2 Department of Thoracic Surgery, Liverpool Heart & Chest Hospital, Liverpool, UK.

Endobronchial metastasis from extrapulmonary solid tumors is rare, and endobronchial metastasis from the prostate is even more unusual. An 80-year-old patient presented with significant dyspnea secondary to metastatic stromal cell sarcoma of the prostate, which occluded the right main bronchus. The tumor, causing complete collapse of the right lung, was found on computed tomography and confirmed by bronchoscopy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0218492319827668DOI Listing
March 2019
15 Reads

Use of MRI-Guided Biopsy for Selection and Follow-up of Men Undergoing Hemi-gland Cryoablation of Prostate Cancer.

Urology 2019 04 16;126:158-164. Epub 2019 Jan 16.

Department of Urology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA. Electronic address:

Objective: To investigate safety, efficacy, and quality of life impact of hemi-gland cryotherapy for clinically-significant prostate cancer (CaP), when patient selection and follow-up includes MRI-guided biopsy.

Methods: Twenty-nine men with unilateral CaP (all clinically significant with prostate volume <60 cc) were enrolled in a prospective observational trial of hemi-gland cryotherapy. Mean patient age was 68. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2018.11.052DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6698362PMC
April 2019
13 Reads

The incidence proportion of erectile dysfunction in patients treated with cryotherapy for prostate cancer: a meta-analysis.

Clin Transl Oncol 2019 Sep 16;21(9):1152-1158. Epub 2019 Jan 16.

The Second Hospital of Tianjin Medical University, Tianjin, People's Republic of China.

Objectives: With the maturity of cryotherapy for prostate cancer, the complications after operation are also decreasing, which can improve the prognosis of patients. However, erectile dysfunction (ED) is still one of the main complications after cryotherapy. Therefore, we performed a meta-analysis to evaluate the incidence of erectile dysfunction in patients after cryotherapy. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s12094-019-02036-8
Publisher Site
http://dx.doi.org/10.1007/s12094-019-02036-8DOI Listing
September 2019
20 Reads

Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry.

Eur Urol 2019 Jul 9;76(1):98-105. Epub 2019 Jan 9.

Division of Surgery, Department of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK; Department of Urology, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, UK.

Background: Focal cryotherapy can be used to treat patients with clinically significant nonmetastatic prostate cancer to reduce side effects.

Objective: Early-medium-term cancer control and functional outcomes.

Design, Setting, And Participants: A prospective registry-based case series of 122 consecutive patients undergoing focal cryotherapy between October 1, 2013, and November 30, 2016, in five UK centres. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S03022838183103
Publisher Site
http://dx.doi.org/10.1016/j.eururo.2018.12.030DOI Listing
July 2019
48 Reads

Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives.

Cancers (Basel) 2018 Dec 3;10(12). Epub 2018 Dec 3.

Department of Radiotherapy, University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands.

Over the last decades, primary prostate cancer radiotherapy saw improving developments, such as more conformal dose administration and hypofractionated treatment regimens. Still, prostate cancer recurrences after whole-gland radiotherapy remain common, especially in patients with intermediate- to high-risk disease. The vast majority of these patients are treated palliatively with androgen deprivation therapy (ADT), which exposes them to harmful side-effects and is only effective for a limited amount of time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers10120480DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6316339PMC
December 2018
3 Reads

Biochemical and magnetic resonance image response in targeted focal cryotherapy to ablate targeted biopsy-proven index lesion of prostate cancer.

Int J Urol 2019 02 28;26(2):317-319. Epub 2018 Nov 28.

Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/iju.13857DOI Listing
February 2019
6 Reads

MR Imaging-Guided Focal Therapies of Prostate Cancer.

Magn Reson Imaging Clin N Am 2019 Feb 29;27(1):131-138. Epub 2018 Oct 29.

Department of Radiology, University of Chicago, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

MR imaging-guided focal therapy is a viable treatment option for patients with localized prostate cancer. After the identification of a malignant focus in the prostate gland on multiparametric MR imaging, treatment can be directed in a precise fashion to the area of interest. The goal of focal therapy is to eradicate prostate cancer while minimizing complications that can affect quality of life. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.mric.2018.08.004DOI Listing
February 2019
33 Reads

[Possibilities of cryotherapy for prostate cancer : Primary cryotherapy for localised or locally advanced prostate cancer].

Authors:
D Wilborn S Schmidt

Urologe A 2018 Dec;57(12):1490-1493

UroEvidence@Deutsche Gesellschaft für Urologie, Nestorstr. 8-9, 10709, Berlin, Deutschland.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s00120-018-0805-1
Publisher Site
http://dx.doi.org/10.1007/s00120-018-0805-1DOI Listing
December 2018
9 Reads

Prostate imaging features that indicate benign or malignant pathology on biopsy.

Transl Androl Urol 2018 Sep;7(Suppl 4):S420-S435

Division of Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.

Accurate diagnosis of clinically significant prostate cancer is essential in identifying patients who should be offered treatment with curative intent. Modifications to the Gleason grading system in recent years show that accurate grading and reporting at needle biopsy can improve identification of clinically significant prostate cancers. Extracapsular extension of prostate cancer has been demonstrated to be an adverse prognostic factor with greater risk of metastatic spread than organ-confined disease. Read More

View Article

Download full-text PDF

Source
http://tau.amegroups.com/article/view/20471/20788
Publisher Site
http://dx.doi.org/10.21037/tau.2018.07.06DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6178322PMC
September 2018
50 Reads

Clinically Localized Prostate Cancer: ASCO Clinical Practice Guideline Endorsement of an American Urological Association/American Society for Radiation Oncology/Society of Urologic Oncology Guideline.

J Clin Oncol 2018 Nov 5;36(32):3251-3258. Epub 2018 Sep 5.

Justin E. Bekelman and Neha Vapiwala, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA; R. Bryan Rumble, American Society of Clinical Oncology, Alexandria, VA; Ronald C. Chen, University of North Carolina at Chapel Hill, Chapel Hill; Stephen J. Freedland, Durham VA Medical Center, Durham, NC; Thomas M. Pisansky, Mayo Clinic, Rochester, MN; Antonio Finelli, Princess Margaret Cancer Centre, University Health Network; Andrew Feifer, Trillium Health Partners, University of Toronto; D. Andrew Loblaw, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Paul L. Nguyen, Dana-Farber Cancer Institute, Boston, MA; Scott T. Tagawa, Weill Cornell Medicine, New York, NY; Silke Gillessen, Kantonsspital St Gallen, St Gallen, Switzerland; Todd M. Morgan, University of Michigan, Ann Arbor, MI; Glenn Liu, University of Wisconsin Carbone Cancer Center, Madison, WI; John J. Haluschak, Kettering Medical Center-Pavillon, Kettering; Andrew Stephenson, Cleveland Clinic, Cleveland, OH; Karim Touijer, Memorial Sloan Kettering Cancer Center, New York, NY; Terry Kungel, Maine Coalition to Fight Prostate Cancer, Augusta, ME; and Stephen J. Freedland, Cedars-Sinai Medical Center, Los Angeles, CA.

Purpose: In April 2017, the American Urological Association, American Society for Radiation Oncology, and Society of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The American Society of Clinical Oncology (ASCO) has a policy and set of procedures for endorsing clinical practice guidelines that have been developed by other professional organizations.

Methods: The Clinically Localized Prostate Cancer guideline was reviewed for developmental rigor by methodologists. Read More

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.18.00606
Publisher Site
http://dx.doi.org/10.1200/JCO.18.00606DOI Listing
November 2018
33 Reads

Primary cryotherapy for localised or locally advanced prostate cancer.

BJU Int 2019 09 2;124(3):383-385. Epub 2019 Jul 2.

Urology Section, Minneapolis VA Health Care System, Minneapolis, MN, USA.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/bju.14519
Publisher Site
http://dx.doi.org/10.1111/bju.14519DOI Listing
September 2019
42 Reads